The Department of Health and Human Services yesterday released initial data on how states and territories plan to use their share of 100 million rapid point-of-care tests for the COVID-19 virus, which the agency began distributing last month.

The initial data includes 32 states and the District of Columbia. The Food and Drug Administration in August authorized laboratories certified to perform moderate, high or waived complexity tests under the Clinical Laboratory Improvement Amendment to use the Abbot BinaxNOW antigen test to detect SARS-CoV-2 in nasal swabs from individuals whose health care provider suspects they have COVID-19 within seven days of symptom onset.

Related News Articles

Headline
The Food and Drug Administration today issued a request for public comment on a series of questions regarding current approaches to evaluating artificial…
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…